Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK
Beta0.86
Shares Outstanding14.6M
Average Volume (10 days)110.7K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($1.03)
Sales (TTM)$10.68
Book Value (MRQ)$19.52
Cash Flow (TTM)$0.30
Cash (MRQ)$5.90

Analyst Views

Current Mean RecommendationHold
Strong Buy0
 
Buy0
 
Hold2
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Michael L. Levitz
EVP, CFO, Treasurer
(2,609)
Dispose
Mar 10, 2023
David Colleran
EVP, General Counsel, Corp Sec
(2,250)
Dispose
Mar 10, 2023
Cheryl R. Blanchard
Director, President, CEO, Director
(13,211)
Dispose
Mar 10, 2023
Michael L. Levitz
EVP, CFO, Treasurer
(1,303)
Dispose
Mar 9, 2023
David Colleran
EVP, General Counsel, Corp Sec
(1,081)
Dispose
Mar 9, 2023

Recent SEC Filings

10-K
Mar 16, 2023
Insider Buy/Sell
Mar 14, 2023
Insider Buy/Sell
Mar 14, 2023
Insider Buy/Sell
Mar 14, 2023
Insider Buy/Sell
Mar 10, 2023
To Top